Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 4 1Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 21Melanoma 20Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 9Pancreatic Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Colonic Neoplasms 3Thyroid Neoplasms 2Meningioma 2Leukemia, Myeloid, Acute 2Glioma 2Breast Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors, KRAS Mutation; SOS1 1Solid Tumors 1Solid Tumor Cancer 1Solid Tumor 1Sarcoma 1Rhabdoid Tumor 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Recurrence 1

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × trametinib × Clear all
NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

University of California, San Francisco

Phase 1 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔